Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Abzena, Baylor Scott & White Research Institute deal

    Abzena plc (LSE:ABZA), Babraham, U.K. Baylor Scott & White Research Institute, Dallas, Texas Business: Autoimmune, Cancer Abzena and the institute formed JV Denceptor Therapeutics Ltd. to develop immunotherapies against…

    Published on 7/25/2016
  • Aeterna Zentaris, Orient Europharma deal

    Aeterna Zentaris Inc. (TSX:AEZ;NASDAQ:AEZS), Quebec City, Quebec Orient Europharma Co. Ltd. (TPEx:4120), Taipei, Taiwan Business: Cancer Aeterna granted Orients Cyntec Co. Ltd. affiliate exclusive rights to develop and …

    Published on 7/25/2016
  • Asklepion Pharmaceuticals, Retrophin deal

    Asklepion Pharmaceuticals LLC, Baltimore, Md. Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Business: Hepatic Retrophin acquired a liquid formulation of ursodeoxycholic acid (UDCA) from Asklepion. Solid formulations of …

    Published on 7/25/2016
  • Avacta, Glythera deal

    Avacta Group plc (LSE:AVCT), Heslington, U.K. Glythera Ltd., Newcastle upon Tyne, U.K. Business: Drug delivery Avacta and Glythera partnered to develop targeted therapeutics using Avactas Affimer technology and …

    Published on 7/25/2016
  • Baylor, Cell Medica deal

    Baylor College of Medicine, Houston, Texas Cell Medica Ltd., London, U.K. Business: Cancer Baylor granted Cell Medica exclusive rights to co-develop and commercialize Baylors cell and gene technologies to treat solid …

    Published on 7/25/2016
  • Bind Therapeutics, Pfizer deal

    Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer Bind accepted a stalking horse bid from Pfizer to acquire substantially all of the biotechs assets for $20 …

    Published on 7/25/2016
  • Georgia State University, Aviragen deal

    Georgia State University, Atlanta, Ga. Aviragen Therapeutics Inc. (NASDAQ:AVIR), Alpharetta, Ga. Business: Infectious Georgia State granted Aviragen exclusive, worldwide rights to co-develop and commercialize a …

    Published on 7/25/2016
  • Jounce Therapeutics, Celgene deal

    Jounce Therapeutics Inc., Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Jounce granted Celgene options to license multiple immuno-oncology programs from Jounce, including lead candidate JTX…

    Published on 7/25/2016
  • Ligand, Gilead deal

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Antibodies Gilead received non-exclusive, worldwide rights to Ligands OmniRat, OmniMouse and …

    Published on 7/25/2016
  • MiaMed, Amicus Therapeutics deal

    MiaMed Inc., New York, N.Y. Amicus Therapeutics Inc. (NASDAQ:FOLD), Cranbury, N.J. Business: Neurology Amicus acquired neurology company MiaMed and its preclinical program for cyclin-dependent kinase-like 5 deficiency. …

    Published on 7/25/2016
  • MRC Technology, DRI Capital deal

    MRC Technology, London, U.K. DRI Capital Inc., Toronto, Ontario Business: Cancer MRC Technology sold a portion of its royalty rights to Keytruda pembrolizumab to DRI Capital for $150 million. The not-for-profit said it …

    Published on 7/25/2016
  • Neovacs, Stellar Biotechnologies deal

    Neovacs S.A. (Euronext:ALNEV), Paris, France Stellar Biotechnologies Inc. (NASDAQ:SBOT), Port Hueneme, Calif. Business: Autoimmune Neovacs and Stellar formed JV Neostell S.A.S. to manufacture and sell Neovacs Kinoid …

    Published on 7/25/2016
  • Open Monoclonal Technology, WuXi PharmaTech deal

    Open Monoclonal Technology Inc., Palo Alto, Calif. WuXi PharmaTech Inc., Shanghai, China Business: Antibodies Ligand Pharmaceuticals Inc. (NASDAQ:LGND, La Jolla, Calif.) said it will receive $4 million in combined …

    Published on 7/25/2016
  • Orexo, Mundipharma deal

    Orexo AB (SSE:ORX), Uppsala, Sweden Mundipharma International Ltd., Cambridge, U.K. Business: Neurology Orexo granted Mundipharma exclusive rights to Zubsolv buprenorphine/naloxone outside the U.S. to treat opioid …

    Published on 7/25/2016
  • Sprint Bioscience deal

    Sprint Bioscience AB, Stockholm, Sweden Business: Cancer Sprint granted an undisclosed U.S. company worldwide rights to develop and commercialize Sprints phosphatidylinositol-5-phosphate 4-kinase type II alpha (PIP4K2A)…

    Published on 7/25/2016
  • Sun Pharma, Sun Pharmaceutical deal

    Sun Pharma Advanced Research Company Ltd. (BSE:524715;NSE:SPARC), Mumbai, India Sun Pharmaceutical Industries Ltd. (BSE:524715;NSE:SUNPHARMA), Mumbai, India Business: Neurology Sun Pharma Advanced Research Co. (SPARC) …

    Published on 7/25/2016
  • Teva, Impax, Allergan deal

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Impax Laboratories Inc. (NASDAQ:IPXL), Hayward, Calif. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Generics Teva will sell a portfolio of …

    Published on 7/25/2016
  • Transition Therapeutics, Opko deal

    Transition Therapeutics Inc. (TSX:TTH;NASDAQ:TTHI), Toronto, Ontario Opko Health Inc. (NYSE:OPK;Tel Aviv:OPK), Miami, Fla. Business: Neurology, Endocrine/Metabolic, Inflammation Opko will acquire Transition for $1.55 …

    Published on 7/25/2016
  • University of Dundee, Boehringer Ingelheim deal

    University of Dundee, Dundee, U.K. Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cancer, Pulmonary Boehringer and the university partnered to develop therapeutics using the universitys proteolysis targeting …

    Published on 7/25/2016
  • Altos Therapeutics, Takeda deal

    Altos Therapeutics LLC, Los Altos, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Gastrointestinal The companies partnered to develop Altos sole asset, ATC-1906. As part of the deal, Takeda …

    Published on 7/18/2016
  • Amgen, Daiichi Sankyo deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Biosimilars Amgen granted Daiichi exclusive rights to commercialize nine biosimilars in Japan. Amgen will be …

    Published on 7/18/2016
  • Bio-Path, Thomas Jefferson University deal

    Bio-Path Holdings Inc. (NASDAQ:BPTH), Houston, Texas Thomas Jefferson University, Philadelphia, Pa. Business: Cancer, Drug delivery Bio-Path and the university partnered to develop Bio-Paths DNAbilize systemic antisense…

    Published on 7/18/2016
  • Broad Institute, Evotec deal

    Broad Institute of MIT and Harvard, Cambridge, Mass. Evotec AG (Xetra:EVT), Hamburg, Germany Business: Functional genomics The institute granted Evotec non-exclusive rights to IP related to its CRISPR-Cas9 (CRISPR-…

    Published on 7/18/2016
  • Celyad, Ono Pharmaceutical deal

    Celyad S.A. (Euronext:CYAD;NASDAQ:CYAD), Mont-Saint-Guibert, Belgium Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Business: Cancer Celyad granted Ono exclusive rights to develop and commercialize its …

    Published on 7/18/2016
  • Daiichi Sankyo, Servier deal

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Servier, Neuilly-sur-Seine, France Business: Cardiovascular Daiichi granted Serviers Servier Canada affiliate rights to commercialize edoxaban in Canada. The oral …

    Published on 7/18/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993